Is it better to take dacomitinib/dacomitinib (Dozerun) on an empty stomach or after a meal?

Dacomitinib/Dacomitinib (Dacomitinib) is a targeted therapy drug that is usually used to treat malignant tumors such as EGFR mutant non-small cell lung cancer. When using dacomitinib, patients are often concerned about the best time and method of taking it, especially the impact of taking it on an empty stomach or after meals on the efficacy and safety of the drug.

According to the drug instructions of dacomitinib and the guidance of clinical studies, dacomitinib can be taken before or after meals, which means that it is less dependent on food. Specifically, the absorption of the drug will not be significantly changed by the presence of food. Therefore, patients do not need to strictly control taking before or after meals when taking dacomitinib. Although the drug is not highly dependent on food, in order to ensure optimal absorption of the drug and reduce gastrointestinal discomfort, it is recommended that patients arrange the medication time according to their own living habits and doctor's recommendations.

Still, it's worth noting that if patients experience gastrointestinal discomfort, such as nausea or vomiting, after taking the medication, they can try taking the medication after a meal to reduce these symptoms. During the medication process, patients should maintain a regular medication schedule to help maintain a stable concentration of the drug in the body, which is very important for maximizing the therapeutic effect. Therefore, although it is not required to take it strictly on an empty stomach or after meals, it is recommended that patients insist on taking dacomitinib at the same time every day, which will help the effective absorption and metabolism of the drug.

In order to ensure the stable effect of dacomitinib and reduce drug interactions, patients should try to take the drug at the same time every day, follow the doctor's recommendations, and avoid using it at the same time with other foods or drugs that may interfere with drug metabolism. By taking these simple measures, patients can effectively reduce adverse reactions and improve the therapeutic effect of dacomitinib.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro